{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:26:02Z","timestamp":1790940362716,"version":"4.1.0"},"reference-count":98,"publisher":"BMJ","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Genet"],"published-print":{"date-parts":[[1984,8]]},"abstract":"<jats:p>There is ample evidence that the human acetylator phenotypes are associated with drug induced phenomena. It is principally the slow acetylators who exhibit toxic adverse effects because of their relative inability to detoxify the original drug compounds. In rare instances, however, it is the rapid acetylators who are at a disadvantage. In the matter of association of spontaneous disease with either acetylator phenotype, there are two groups of disorders to consider. First, disorders in which carcinogenic amines are known to be an aetiological factor. This is because these amines are substrates for the polymorphic N-acetyltransferase activity and hence there is a possible rational basis for searching for an association. Secondly, other disorders where searches for associations are based more on hunches. In the first group there is a definite statistical association between cancer of the bladder and the slow acetylator phenotype. In prevalence studies the slow phenotype is 39% more associated with bladder cancer than is the rapid phenotype. On the basis of the evidence now available it is not possible to say whether this association is because slow acetylators develop the disease more frequently or whether they survive longer. In the second group the relevant studies show (1) a greatly increased prevalence of slow acetylators in Gilbert's disease; (2) a confirmed association between the rapid acetylator phenotype and diabetes; (3) a possible association between the rapid acetylator phenotype and breast cancer; (4) a possible association between the slow acetylator phenotype and leprosy in Chinese patients; (5) an earlier age of onset of thyrotoxicosis (Graves' disease) in slow acetylators than in rapid acetylators; (6) no evidence of an association between either phenotype and spontaneous systemic lupus erythematosus.<\/jats:p>","DOI":"10.1136\/jmg.21.4.243","type":"journal-article","created":{"date-parts":[[2008,11,10]],"date-time":"2008-11-10T15:09:16Z","timestamp":1226329756000},"page":"243-253","source":"Crossref","is-referenced-by-count":47,"title":["Survey of the human acetylator polymorphism in spontaneous disorders."],"prefix":"10.1136","volume":"21","author":[{"given":"D A","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[1984,8,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/jama.1975.03240200044026","article-title":"Criteria for classification of systemic lupus erythematosus","volume":"231","author":"Rabham, N.B.; Minkin, W.","year":"1975","unstructured":"Rabham NB, Minkin W. Criteria for classification of systemic lupus erythematosus. JAMA 1975;231:846.","journal-title":"JAMA"},{"key":"ref_2","first-page":"100","article-title":"Inaktivering av medikamenter ved acetylering","volume":"2","author":"Walstad, R.A.","year":"1975","unstructured":"Walstad RA. Inaktivering av medikamenter ved acetylering. Tidsskr NorLaegeforen 1975;2:100-3.","journal-title":"Tidsskr NorLaegeforen"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cpt1972133420","article-title":"Relation of hydralazine plasma concentration to dosage and hypotensive action","volume":"13","author":"Zacest, R.; Koch-Weser, J.","year":"1972","unstructured":"Zacest R, Koch-Weser J. Relation of hydralazine plasma concentration to dosage and hypotensive action. Clin Pharmacol Ther 1972;13:420-5.","journal-title":"Clin Pharmacol Ther"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/ard.38.2.171","article-title":"Acetylator phenotype in spontaneous SLE and rheumatoid arthritis","volume":"38","author":"Lawson, D.H.; Henry, D.A.; Lowe, J.; Reavey, P.; Rennie, J.A.N.; Solomon, A.","year":"1979","unstructured":"Lawson DH, Henry DA, Lowe J, Reavey P, Rennie JAN, Solomon A. Acetylator phenotype in spontaneous SLE and rheumatoid arthritis. Ann Rheum Dis 1979;38:171-3.","journal-title":"Ann Rheum Dis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jmg.6.4.405","article-title":"An improved and simplified method of detecting the acetylator phenotype","volume":"6","author":"Evans, D.A.P.","year":"1969","unstructured":"Evans DAP. An improved and simplified method of detecting the acetylator phenotype. J Med Genet 1969; 6:405-7.","journal-title":"J Med Genet"},{"key":"ref_6","first-page":"181","article-title":"Lupus erythemateux dissemine et taux d'isoniazide actif","volume":"124","author":"Godeau, P.; Aubert, M.; Imbert, J.C.; Herreman, G.","year":"1973","unstructured":"Godeau P, Aubert M, Imbert JC, Herreman G. Lupus erythemateux dissemine et taux d'isoniazide actif. Ann Med Interne (Paris) 1973;124:181-6.","journal-title":"Ann Med Interne (Paris)"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2125.1975.tb00562.x","article-title":"Determination of acetylator status in uraemia","volume":"2","author":"Fine, A.; Sumner, D.J.","year":"1975","unstructured":"Fine A, Sumner DJ. Determination of acetylator status in uraemia. Br J Clin Pharmacol 1975;2:475-6.","journal-title":"Br J Clin Pharmacol"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.0954-6820.1981.tb11636.x","article-title":"Evaluation of the sulphadimidine acetylator phenotyping test in patients with reduced renal function","volume":"209","author":"Hall, S.","year":"1981","unstructured":"Hall S. Evaluation of the sulphadimidine acetylator phenotyping test in patients with reduced renal function. Act Med Scand 1981;209:505-7.","journal-title":"Act Med Scand"},{"key":"ref_9","first-page":"1275","article-title":"Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy","volume":"i:","author":"Levi, A.J.; Sherlock, S.; Walker, D.","year":"1968","unstructured":"Levi AJ, Sherlock S, Walker D. Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet 1968;i:1275-9.","journal-title":"Lancet"},{"key":"ref_10","first-page":"541","volume":"25","author":"Alc, Q.J.Stiud","year":"1965","unstructured":"Q J Stiud Alc 1965;25:541-3."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1136\/bmj.2.6147.1260","article-title":"Ethanol-induced increase in drug acetylation in man and isolated rat cells","volume":"ii:","author":"Olsen, H.; Morland, J.","year":"1978","unstructured":"Olsen H, Morland J. Ethanol-induced increase in drug acetylation in man and isolated rat cells. Br Med J 1978; ii: 1260-2.","journal-title":"Br Med J"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2125.1982.tb01357.x","article-title":"Ethanol-induced increase in procainamide acetylation in man","volume":"13","author":"Olsen, H.; Morland, J.","year":"1982","unstructured":"Olsen H, Morland J. Ethanol-induced increase in procainamide acetylation in man. Br J Clin Pharmacol 1982; 13:203-8.","journal-title":"Br J Clin Pharmacol"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2125.1979.tb00899.x","article-title":"Metabolism of sulphadiazine in malnutrition","volume":"7","author":"Shastri, R.A.; Krishnaswamy, K.","year":"1979","unstructured":"Shastri RA, Krishnaswamy K. Metabolism of sulphadiazine in malnutrition. Br J Clin Pharmacol 1979;7:69-73.","journal-title":"Br J Clin Pharmacol"},{"key":"ref_14","first-page":"194","article-title":"Undernourished adults and acetylation phenotype","volume":"20","author":"Shastri, R.A.","year":"1982","unstructured":"Shastri RA. Undernourished adults and acetylation phenotype. Int J Clin Pharmacol Ther Toxicol 1982;20: 194-6.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"67-71","key":"ref_15","first-page":"16","article-title":"The determination of the acetylator phenotype of tuberculosis patients in Czechoslovakia using sulphadimidine","volume":"54","author":"Viznerova, A.; Sladikova, Z.; Ellard, G.A.","year":"1973","unstructured":"Viznerova A, Sladikova Z, Ellard GA. The determination of the acetylator phenotype of tuberculosis patients in Czechoslovakia using sulphadimidine. Tutbercle 1973;54: 67-71. 16 du Souichi P, Courteau H. Induction of acetylating capacity with complete Freund's adjuvant and hydrocortisone in the rabbit. Druig iMetab Dispos 1981;9:279-83.","journal-title":"Tutbercle; Induction of acetylating capacity with complete Freund's adjuvant and hydrocortisone in the rabbit. Druig iMetab Dispos"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000225282","article-title":"Acetylator phenotype in patients with breast cancer","volume":"35","author":"Bulovskaya, L.N.; Krupkin, R.G.; Bochina, T.A.; Shipkova, A.A.; Pavlova, M.V.","year":"1978","unstructured":"Bulovskaya LN, Krupkin RG, Bochina TA, Shipkova AA, Pavlova MV. Acetylator phenotype in patients with breast cancer. Oncology 1978;35:185-8.","journal-title":"Oncology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/bjc.1977.91","article-title":"p-aminosalicylate metabolism in cancer patients sensitive and resistant to chemotherapy","volume":"35","author":"Lavigne, J.G.; Barry, A.; d'Auteuil, C.; Delage, J.M.","year":"1977","unstructured":"Lavigne JG, Barry A, d'Auteuil C, Delage JM. p-aminosalicylate metabolism in cancer patients sensitive and resistant to chemotherapy. Br J Cancer 1977;35:580-6.","journal-title":"Br J Cancer"},{"key":"ref_18","first-page":"725","article-title":"ABO blood groups and secretor character in duodenal ulcer-population and sibship studies","volume":"ii:","author":"Clarke, C.A.; Edwards, J.W.L.; Haddock, D.R.W.; Howel-Evans, A.W.; McConnell, R.B.","year":"1956","unstructured":"Clarke CA, Edwards JWL, Haddock DRW, Howel-Evans AW, McConnell RB. ABO blood groups and secretor character in duodenal ulcer-population and sibship studies. Br MedJ 1956;ii:725-31.","journal-title":"Br MedJ"},{"key":"ref_19","first-page":"177","article-title":"Lea blood group substance degradation in the human alimentary tract and urinary Lea in coeliac disease","volume":"43","author":"Evans, D.A.P.; Donohoe, W.T.A.; Hewitt, S.; Linaker, B.D.","year":"1982","unstructured":"Evans DAP, Donohoe WTA, Hewitt S, Linaker BD. Lea blood group substance degradation in the human alimentary tract and urinary Lea in coeliac disease. Vox Sang 1982;43:177-87.","journal-title":"Vox Sang"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/jmg.20.5.330","article-title":"The association of the slow acetylator phenotype with bladder cancer","volume":"20","author":"Evans, D.A.P.; Eze, L.C.; Whibley, E.J.","year":"1983","unstructured":"Evans DAP, Eze LC, Whibley EJ. The association of the slow acetylator phenotype with bladder cancer. J Med Genet 1983;20:330-3.","journal-title":"J Med Genet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1469-1809.1955.tb01285.x","article-title":"The estimation and significance of the logarithm of a ratio of frequence","volume":"20","author":"Haldane, J.B.S.","year":"1955","unstructured":"Haldane JBS. The estimation and significance of the logarithm of a ratio of frequence. Ann Huim Genet 1955; 20:309-11.","journal-title":"Ann Huim Genet"},{"issue":"19","key":"ref_22","first-page":"251","article-title":"On estimating the relation between blood group and disease","volume":"1954","author":"Woolf, B.","unstructured":"Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1954:19:251-3.","journal-title":"Ann Hum Genet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1289\/ehp.792971","article-title":"N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark","volume":"29","author":"GM, Jr, Lower; T, Nilsson; CE, Neson; H, Wolf; TE, Gamsky; GT, Bryan","year":"1979","unstructured":"Lower GM Jr, Nilsson T, Neson CE, Wolf H, Gamsky TE, Bryan GT. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect 1979;29:71-9.","journal-title":"Environ Health Perspect"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0140-6736(82)90810-8","article-title":"Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer","volume":"ii:","author":"Cartwright, R.A.; Rogers, H.J.; Barham-Hall, D.","year":"1982","unstructured":"Cartwright RA, Rogers HJ, Barham-Hall D, et al. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982;ii:842-6.","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/096032718200100411","article-title":"N-acetylation phenotype in bladder cancer","volume":"1","year":"1982","unstructured":"Woodhouse KW, Adams PC, Clothier A, Mucklow JC, Rawlins MD. N-acetylation phenotype in bladder cancer. Hum Toxicol 1982;1:443-5.","journal-title":"Hum Toxicol"},{"key":"ref_26","first-page":"467","article-title":"A filter paper method for determining isoniazid acetylator phenotype","volume":"26","author":"Weber, W.W.; Brenner, W.","year":"1974","unstructured":"Weber WW, Brenner W. A filter paper method for determining isoniazid acetylator phenotype. Am J Hum Genet 1974:26:467-73.","journal-title":"Am J Hum Genet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2362.1978.tb00856.x","article-title":"Polymorphic acetylation and aminopyrine demethylation in Gilbert's syndrome","volume":"8","author":"Platzer, R.; Kupfer, A.; Bircher, J.; Preisig, R.","year":"1978","unstructured":"Platzer R, Kupfer A, Bircher J, Preisig R. Polymorphic acetylation and aminopyrine demethylation in Gilbert's syndrome. EurJ Clin Invest 1978;8:219-23.","journal-title":"EurJ Clin Invest"},{"key":"ref_28","first-page":"79","article-title":"Fenotipo acetilador en la enfermedad de Basedow","volume":"41","author":"Ladero, J.M.; Cano, F.","year":"1983","unstructured":"Ladero JM, Cano F. Fenotipo acetilador en la enfermedad de Basedow. N Arch Fac Med 1983;41:79-81.","journal-title":"N Arch Fac Med"},{"key":"ref_29","first-page":"423","article-title":"The rate of isoniazid inactivation in Finnish diabetic and non-diabetic patients","volume":"45","author":"Mattila, M.J.; Tiitinen, H.","year":"1967","unstructured":"Mattila MJ, Tiitinen H. The rate of isoniazid inactivation in Finnish diabetic and non-diabetic patients. Ann Med Exp Biol Fenn 1967;45:423-7.","journal-title":"Ann Med Exp Biol Fenn"},{"key":"ref_30","first-page":"208","article-title":"Diabetic dimorphism according to acetylator status","volume":"i:","author":"Burrows, A.W.; Hockaday, T.D.R.; Mann, J.I.; Taylor, J.G.","year":"1978","unstructured":"Burrows AW, Hockaday TDR, Mann JI, Taylor JG. Diabetic dimorphism according to acetylator status. Br MedJ 1978;i:208-10.","journal-title":"Br MedJ"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/bmj.2.6082.291","article-title":"Acetylator phenotype in diabetic neuropathy","volume":"ii:","author":"McLaren, E.H.; Burden, A.C.; Moorhead, P.J.","year":"1977","unstructured":"McLaren EH, Burden AC, Moorhead PJ. Acetylator phenotype in diabetic neuropathy. Br Med J 1977;ii: 291-3.","journal-title":"Br Med J"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2337\/diab.30.11.907","article-title":"Acetylator phenotypes and type I (insulin-dependent) diabetics with microvascular disease","volume":"30","year":"1981","unstructured":"Acetylator phenotypes and type I (insulin-dependent) diabetics with microvascular disease. Diabetes 1981;30: 907-10.","journal-title":"Diabetes"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/BF00282587","article-title":"Acetylator status and diabetic neuropathy","volume":"22","author":"Shenfield, G.M.; McCann, V.J.; Tjokresetio, R.","year":"1982","unstructured":"Shenfield GM, McCann VJ, Tjokresetio R. Acetylator status and diabetic neuropathy. Diabetologia 1982;22: 441-4.","journal-title":"Diabetologia"},{"key":"ref_34","first-page":"187","article-title":"Hepatic acetylator phenotype in diabetes mellitus","volume":"14","author":"Ladero, J.M.; Arrojo, A.; de Salamanca, R.E.; Gomez, M.; Cano, F.; Alfonso, M.","year":"1982","unstructured":"Ladero JM, Arrojo A, de Salamanca RE, Gomez M, Cano F, Alfonso M. Hepatic acetylator phenotype in diabetes mellitus. Ann Clin Res 1982;14:187-9.","journal-title":"Ann Clin Res"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1136\/bmj.3.5825.506","article-title":"Simplified method for determining acetylator phenotype","volume":"3","author":"Schroder, H.","year":"1972","unstructured":"Schroder H. Simplified method for determining acetylator phenotype. Br MedJ 1972;3:506-7.","journal-title":"Br MedJ"},{"key":"ref_36","first-page":"394","article-title":"Human acetylation polymorphism","volume":"63","author":"Evans, D.A.P.; White, T.A.","year":"1964","unstructured":"Evans DAP, White TA. Human acetylation polymorphism. JLab Clin Med 1964;63:394-403.","journal-title":"JLab Clin Med"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0041-3879(64)80071-4","article-title":"A study of the influence of the isoniazid inactivator phenotype on reversion in genitourinary tuberculosis","volume":"45","author":"Gow, J.G.; Evans, D.A.P.","year":"1964","unstructured":"Gow JG, Evans DAP. A study of the influence of the isoniazid inactivator phenotype on reversion in genitourinary tuberculosis. Tubercle 1964;45:136-43.","journal-title":"Tubercle"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/cpt19689180","article-title":"The acetylation of sulfamethazine and sulfamethoxypyridazine by human subjects","volume":"9","author":"White, T.A.; Evans, D.A.P.","year":"1968","unstructured":"White TA, Evans DAP. The acetylation of sulfamethazine and sulfamethoxypyridazine by human subjects. Clin Pharmacol Ther 1968;9:80-8.","journal-title":"Clin Pharmacol Ther"},{"key":"ref_39","article-title":"methylation and schizophrenia. A pharmacogenetic study","author":"Demethylation, Price J.","year":"1971","unstructured":"Price J. Demethylation, methylation and schizophrenia. A pharmacogenetic study. MD thesis, University of London, 1971."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/jmg.9.1.53","article-title":"Antinuclear factor in rapid and slow acetylator patients treated with isoniazid","volume":"9","author":"Evans, D.A.P.; Bullen, M.G.; Houston, J.; Hopkins, C.A.; Vetters, J.M.","year":"1972","unstructured":"Evans DAP, Bullen MG, Houston J, Hopkins CA, Vetters JM. Antinuclear factor in rapid and slow acetylator patients treated with isoniazid. J Med Genet 1972;9: 53-6.","journal-title":"J Med Genet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/jmg.9.1.57","article-title":"The use of the Autoanalyser to determine the acetylator phenotype","volume":"9","author":"Eze, L.C.; Evans, D.A.P.","year":"1972","unstructured":"Eze LC, Evans DAP. The use of the Autoanalyser to determine the acetylator phenotype. J Med Genet 1972;9: 57-9.","journal-title":"J Med Genet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/jmg.9.2.168","article-title":"The polymcrphic acetylation of sulphapyridine in man","volume":"9","author":"Schroder, H.; Evans, D.A.P.","year":"1972","unstructured":"Schroder H, Evans DAP. The polymcrphic acetylation of sulphapyridine in man. J Med Genet 1972;9:168-71.","journal-title":"J Med Genet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/gut.13.4.278","article-title":"Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects","volume":"13","author":"Schroder, H.; Evans, D.A.P.","year":"1972","unstructured":"Schroder H, Evans DAP. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut 1972;13:278-84.","journal-title":"Gut"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cpt1973145802","article-title":"Metabolism of salicylazosulfapyridine in healthy subjects and in patients with ulcerative colitis","volume":"14","author":"Schroder, H.; Lewkonia, R.M.; Evans, D.A.P.","year":"1973","unstructured":"Schroder H, Lewkonia RM, Evans DAP. Metabolism of salicylazosulfapyridine in healthy subjects and in patients with ulcerative colitis. Clin Pharmacol Ther 1973;14: 802-9.","journal-title":"Clin Pharmacol Ther"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0041-3879(75)90053-7","article-title":"Determination of the acetylator phenotype using matrix isoniazid","volume":"56","author":"Ellard, G.A.; Gammon, P.T.; Tiitinen, H.","year":"1975","unstructured":"Ellard GA, Gammon PT, Tiitinen H. Determination of the acetylator phenotype using matrix isoniazid. Tubercle 1975;56:203-9.","journal-title":"Tubercle"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/jmg.13.1.17","article-title":"Polymorphic acetylation of nitrazepam","volume":"13","author":"Karim, A.K.M.B.; Evans, D.A.P.","year":"1976","unstructured":"Karim AKMB, Evans DAP. Polymorphic acetylation of nitrazepam. J Med Genet 1976;13:17-9.","journal-title":"J Med Genet"},{"key":"ref_47","first-page":"423","article-title":"Effects of oral glucose on isoniazid kinetics","volume":"11","year":"1981","unstructured":"Thom S, Farrow PR, Santoso B, Alberti KGMM, Rawlins MD. Effects of oral glucose on isoniazid kinetics. BrJClinPharmacol 1981;11:423P.","journal-title":"BrJClinPharmacol"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/cpt196564430","article-title":"The influence of acetylator phenotype on the effects of treating depression with phenelzine","volume":"6","author":"Evans, D.A.P.; Davison, K.; Pratt, R.T.C.","year":"1965","unstructured":"Evans DAP, Davison K, Pratt RTC. The influence of acetylator phenotype on the effects of treating depression with phenelzine. Clin Pharmacol Ther 1965;6:430-5.","journal-title":"Clin Pharmacol Ther"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2125.1978.tb04593.x","article-title":"The influence of acetylator phenotype on the outcome of treatment with phenelzine in a clinical trial","volume":"6","author":"Marshall, E.F.; Mountjoy, C.Q.; Campbell, I.C.; Garside, R.F.; Leitch, I.M.; Roth, M.","year":"1978","unstructured":"Marshall EF, Mountjoy CQ, Campbell IC, Garside RF, Leitch IM, Roth M. The influence of acetylator phenotype on the outcome of treatment with phenelzine in a clinical trial. Br J Clin Pharmacol 1978;6:247-54.","journal-title":"Br J Clin Pharmacol"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2125.1976.tb04887.x","article-title":"Phenelzine in urine: assay and relation to acetylator status","volume":"3","author":"Caddy, B.; Tilstone, W.J.; Johnston, E.C.","year":"1976","unstructured":"Caddy B, Tilstone WJ, Johnston EC. Phenelzine in urine: assay and relation to acetylator status. Br J Clin Pharmacol 1976;3:633-7.","journal-title":"Br J Clin Pharmacol"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0140-6736(73)90715-0","article-title":"Acetylator status and response to phenelzine in depressed patients","volume":"ji:","author":"Johnstone, E.D.; Marsh, W.","year":"1973","unstructured":"Johnstone ED, Marsh W. Acetylator status and response to phenelzine in depressed patients. Lancet 1973 ji:567-70.","journal-title":"Lancet"},{"issue":"47","key":"ref_52","first-page":"303","article-title":"Inactivation of isoniazid and sulphadimidine in Mongoloid subjects","volume":"1969","unstructured":"Airaksinen E, Mattila MJ, Ollila 0. Inactivation of isoniazid and sulphadimidine in Mongoloid subjects. Ann MedExp Biol Fenn 1969;47:303-7.","journal-title":"Ann MedExp Biol Fenn"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/00365526709180084","article-title":"The acetylator phenotypes of duodenal ulcer patients","volume":"2","author":"Evans, D.A.P.","year":"1967","unstructured":"Evans DAP. The acetylator phenotypes of duodenal ulcer patients. ScandJ Gastroenterol 1967;2:289-92.","journal-title":"ScandJ Gastroenterol"},{"issue":"7","key":"ref_54","first-page":"209","article-title":"Absorption of ethionamide, isoniazid and aminosalicylic acid from the post-resection gastrointestinal tract","volume":"1969","author":"Mattila, M.J.; Frimen, A.; Larmi, T.K.I.; Koskinen, R.","unstructured":"Mattila MJ, Frimen A, Larmi TKI, Koskinen R. Absorption of ethionamide, isoniazid and aminosalicylic acid from the post-resection gastrointestinal tract. Ann Med Exp Biol Fenn 1969;7:209-12.","journal-title":"Ann Med Exp Biol Fenn"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/cpt1975185part1514","article-title":"Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease","volume":"18","author":"Das, K.M.; Eastwood, M.A.","year":"1975","unstructured":"Das KM, Eastwood MA. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease. Clin Pharmacol Ther 1975;18:514-20.","journal-title":"Clin Pharmacol Ther"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF00627927","article-title":"Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease","volume":"21","author":"Sharp, M.E.; Wallace, S.M.; Hindmarsh, K.W.; Brown, M.A.","year":"1981","unstructured":"Sharp ME, Wallace SM, Hindmarsh KW, Brown MA. Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease. Eur J Clin Pharmacol 1981;21:243-50.","journal-title":"Eur J Clin Pharmacol"},{"key":"ref_57","first-page":"323","article-title":"Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease","volume":"2","author":"Clarke, D.F.; George, D.; Milsap, R.L.","year":"1982","unstructured":"Clarke DF, George D, Milsap RL, et al. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease. Pediatr Pharmacol 1982;2: 323-33.","journal-title":"Pediatr Pharmacol"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/jmg.20.1.30","article-title":"The effect of the acetylator phenotype on the metabolism of sulphasalazine in man","volume":"20","author":"Khan, A.K.A.; Nurazzaman, M.; Truelove, S.C.","year":"1983","unstructured":"Khan AKA, Nurazzaman M, Truelove SC. The effect of the acetylator phenotype on the metabolism of sulphasalazine in man. JMed Genet 1983;20:30-6.","journal-title":"JMed Genet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/art.1780230508","article-title":"Acetylator phenotype in idopathic systemic lupus erythematosus","volume":"23","author":"Reidenberg, M.M.; Levy, M.; Drayer, D.R.; Zylber-Katz, E.; Robbins, W.C.","year":"1980","unstructured":"Reidenberg MM, Levy M, Drayer DR, Zylber-Katz E, Robbins WC. Acetylator phenotype in idopathic systemic lupus erythematosus. Arthritis Rheum 1980;23:569-73.","journal-title":"Arthritis Rheum"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0378-4347(00)81919-2","article-title":"High performance liquid chromatographic determination of aminosalicylate, sulfapyridine and their metabolites. Its application for pharmacokinetic studies with salicylazosulfapyridine in Man","volume":"162","author":"Fisher, C.; Klotz, U.","year":"1979","unstructured":"Fisher C, Klotz U. High performance liquid chromatographic determination of aminosalicylate, sulfapyridine and their metabolites. Its application for pharmacokinetic studies with salicylazosulfapyridine in Man. J Chromatogr 1979;162:237-43.","journal-title":"J Chromatogr"},{"key":"ref_61","first-page":"224","article-title":"The application of urine tests to monitor the regularity of dapsone selfadministration","volume":"45","author":"Ellard, G.A.; Gammon, P.T.; Harris, J.M.","year":"1974","unstructured":"Ellard GA, Gammon PT, Harris JM. The application of urine tests to monitor the regularity of dapsone selfadministration. Lepr Rev 1974;45:224-34.","journal-title":"Lepr Rev"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/239159a0","article-title":"Dapsone acetylation and the treatment of leprosy","volume":"239","author":"Ellard, G.A.; Gammon, P.T.; Helmy, H.S.; Rees, R.J.W.","year":"1972","unstructured":"Ellard GA, Gammon PT, Helmy HS, Rees RJW. Dapsone acetylation and the treatment of leprosy. Nature 1972;239:159-60.","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"963","DOI":"10.4269\/ajtmh.1975.24.963","article-title":"Dapsone metabolism in patients with dapsone-resistant leprosy","volume":"24","author":"Gelber, R.H.; Rees, R.J.W.","year":"1975","unstructured":"Gelber RH, Rees RJW. Dapsone metabolism in patients with dapsone-resistant leprosy. Am J Trop Med Hyg 1975; 24:963-7.","journal-title":"Am J Trop Med Hyg"},{"key":"ref_64","first-page":"441","article-title":"Dapsone acetylation in dermatitis herpetiformis","volume":"90","author":"Ellard, G.A.; Gammon, P.T.; Savin, J.A.; Tan, R.S.H.","year":"1974","unstructured":"Ellard GA, Gammon PT, Savin JA, Tan RSH. Dapsone acetylation in dermatitis herpetiformis. Br J Dermatol 1974;90:441-4.","journal-title":"Br J Dermatol"},{"key":"ref_65","first-page":"308","article-title":"Acetylator phenotype, minimal maintenance dose and haemolytic effect of dapsone in dermatitis herpetiformis","volume":"6","author":"Forstrom, L.; Mattila, M.J.; Mustakallio, K.K.","year":"1974","unstructured":"Forstrom L, Mattila MJ, Mustakallio KK. Acetylator phenotype, minimal maintenance dose and haemolytic effect of dapsone in dermatitis herpetiformis. Ann Clin Res 1974;6:308-10.","journal-title":"Ann Clin Res"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2133.1983.tb04583.x","article-title":"Pharmacokinetic observations on dapsone in dermatitis herpetiformis","volume":"108","author":"Swain, A.F.; Ahmad, R.A.; Rogers, H.J.; Leonard, J.N.; Fry, L.","year":"1983","unstructured":"Swain AF, Ahmad RA, Rogers HJ, Leonard JN, Fry L. Pharmacokinetic observations on dapsone in dermatitis herpetiformis. Br J Dermatol 1983;108:91-8.","journal-title":"Br J Dermatol"},{"key":"ref_67","first-page":"114","article-title":"Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine","volume":"76","author":"Perry, H.M.; Tan, E.M.; Carmody, S.; Sakamoto, A.","year":"1970","unstructured":"Perry HM, Tan EM, Carmody S, Sakamoto A. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. JLab Clin Med 1970;76:114-25.","journal-title":"JLab Clin Med"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.0954-6820.1975.tb04922.x","article-title":"Acetylator phenotype and the anti-hypertensive response to hydralazine","author":"Jounela, A.J.; Pasanen, M.; Mattila, M.J.","year":"1975","unstructured":"Jounela AJ, Pasanen M, Mattila MJ. Acetylator phenotype and the anti-hypertensive response to hydralazine. Acta Med Scand 1975;197:303-6.","journal-title":"Acta Med Scand"},{"key":"ref_69","first-page":"119","article-title":"Dihydralazine therapy and acetylator phenotype","volume":"17","author":"lisalo E; T, Laine; A, Lehtonen; R, Sellman","year":"1979","unstructured":"lisalo E, Laine T, Lehtonen A, Sellman R. Dihydralazine therapy and acetylator phenotype. Int J Clin Pharmacol Biopharm 1979;17:119-24.","journal-title":"Int J Clin Pharmacol Biopharm"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/bmj.284.6320.936","article-title":"Hydralazine, antinuclear antibodies and the lupus syndrome","volume":"284","author":"R, Mansilla Tinoco; SJ, Harland; PJ, Ryan","year":"1982","unstructured":"Mansilla Tinoco R, Harland SJ, Ryan PJ, et al. Hydralazine, antinuclear antibodies and the lupus syndrome. Br MedJ 1982;284:936-9.","journal-title":"Br MedJ"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF00563559","article-title":"Significance of the acetylator phenotype and the therapeutic effect of procainamide","volume":"15","author":"Schroder, P.; Klitgaard, N.A.; Simonsen, E.","year":"1979","unstructured":"Schroder P, Klitgaard NA, Simonsen E. Significance of the acetylator phenotype and the therapeutic effect of procainamide. Eur J Clin Pharmacol 1979;15:63-8.","journal-title":"Eur J Clin Pharmacol"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.0954-6820.1977.tb15685.x","article-title":"Evaluation of the sulphapyridine acetylator phenotyping test in healthy subjects and in patients with cardiac and renal disease","author":"Molin, L.; Larsson, R.; Karlsson, E.","year":"1977","unstructured":"Molin L, Larsson R, Karlsson E. Evaluation of the sulphapyridine acetylator phenotyping test in healthy subjects and in patients with cardiac and renal disease. Acta Med Scand 1977;201:217-22.","journal-title":"Acta Med Scand"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1365-2125.1976.tb00352.x","article-title":"Acetylator phenotype and the clinical pharmacology of slow-release procainamide","volume":"3","author":"Campbell, W.; Tilstone, W.J.; Lawson, D.H.; Hutton, I.; Lawrie, T.D.V.","year":"1976","unstructured":"Campbell W, Tilstone WJ, Lawson DH, Hutton I, Lawrie TDV. Acetylator phenotype and the clinical pharmacology of slow-release procainamide. Br J Clin Pharmacol 1976;3:1023-6.","journal-title":"Br J Clin Pharmacol"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(68)91530-4","article-title":"Renal clearance of sodium sulphadimidine in normal and uraemic subjects","volume":"ii:","author":"Williams, D.M.; Wimpenny, J.; Asscher, A.W.","year":"1968","unstructured":"Williams DM, Wimpenny J, Asscher AW. Renal clearance of sodium sulphadimidine in normal and uraemic subjects. Lancet 1968;ii:1058-60.","journal-title":"Lancet"},{"key":"ref_75","first-page":"29","article-title":"Acetylation phenotype in rheumatoid arthritis","volume":"7","author":"Oka, M, Seppala 0","year":"1978","unstructured":"Oka M, Seppala 0. Acetylation phenotype in rheumatoid arthritis. ScandJRheumatol 1978;7:29-30.","journal-title":"ScandJRheumatol"},{"key":"ref_76","first-page":"196","article-title":"Predominance of slow acetylators among patients with rheumatoid arthritis","volume":"2","author":"Ehrlich, G.E.; Freeman-Narrod, M.; Wineburgh, G.S.","year":"1979","unstructured":"Ehrlich GE, Freeman-Narrod M, Wineburgh GS. Predominance of slow acetylators among patients with rheumatoid arthritis. Eur J Rheumatol Inflam 1979;2: 196-8.","journal-title":"Eur J Rheumatol Inflam"},{"key":"ref_77","first-page":"368","article-title":"Acetylator phenotype in rheumatoid arthritis","volume":"19","author":"Ehrenfeld, M.; Levy, M.; Zylber-Katz, E.","year":"1983","unstructured":"Ehrenfeld M, Levy M, Zylber-Katz E. Acetylator phenotype in rheumatoid arthritis. Isr J Med Sci 1983;19: 368-70.","journal-title":"Isr J Med Sci"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00408229","article-title":"Hepatic acetylator phenotype in porphyria cutanea tarda","volume":"270","author":"Ladero, J.M.; de Salamanca, R.E.; Chinarro, S.","year":"1981","unstructured":"Ladero JM, de Salamanca RE, Chinarro S. Hepatic acetylator phenotype in porphyria cutanea tarda. Arch Dermatol Res 1981;270:171-3.","journal-title":"Arch Dermatol Res"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"641","DOI":"10.4269\/ajtmh.1975.24.641","article-title":"Polymorphic acetylation of the antibacterials sulfamethazine and dapsone in South Indian subjects","volume":"24","author":"Peters, J.H.; Gordon, G.R.; Karat, A.B.","year":"1975","unstructured":"Peters JH, Gordon GR, Karat AB. Polymorphic acetylation of the antibacterials sulfamethazine and dapsone in South Indian subjects. Am J Trop Med Hyg 1975;24: 641-8.","journal-title":"Am J Trop Med Hyg"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/jmg.18.5.325","article-title":"Human acetylator polymorphism: estimate of allele frequency in Libya and details of global distribution","volume":"18","author":"Karim, A.K.M.B.; Elfellah, M.S.; Evans, D.A.P.","year":"1981","unstructured":"Karim AKMB, Elfellah MS, Evans DAP. Human acetylator polymorphism: estimate of allele frequency in Libya and details of global distribution. J Med Genet 1981;18:325-30.","journal-title":"J Med Genet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1139\/y79-117","article-title":"Isoniazid phenotyping of black as well as white patients","volume":"57","author":"Hodgkin, M.M.; Eidus, L.; Bailey, W.C.","year":"1979","unstructured":"Hodgkin MM, Eidus L, Bailey WC. Isoniazid phenotyping of black as well as white patients. Can J Physiol Pharmacol 1979;57:760-3.","journal-title":"Can J Physiol Pharmacol"},{"key":"ref_82","first-page":"885","article-title":"Isoniazid levels in black patients dosed with a matrix preparation (Tebesium)","volume":"31","author":"Glatthaar, E.; Gartig, D.; Stander, M.F.; Kleeberg, H.H.","year":"1977","unstructured":"Glatthaar E, Gartig D, Stander MF, Kleeberg HH. Isoniazid levels in black patients dosed with a matrix preparation (Tebesium). Prax Pneumol 1977;31:885-9.","journal-title":"Prax Pneumol"},{"key":"ref_83","first-page":"311","article-title":"Comparison of isoniazid phenotyping of black and white patients with emphasis on South African blacks","volume":"17","author":"Eidus, L.; Glatthaar, E.; Hodgkin, M.M.; Nel, E.E.; Kleeberg, H.H.","year":"1979","unstructured":"Eidus L, Glatthaar E, Hodgkin MM, Nel EE, Kleeberg HH. Comparison of isoniazid phenotyping of black and white patients with emphasis on South African blacks. Int J Clin Pharmacol Biopharm 1979;17:311-6.","journal-title":"Int J Clin Pharmacol Biopharm"},{"key":"ref_84","first-page":"93","article-title":"Genetic aspect of isoniazid metabolism","volume":"8","author":"Sunahara, S.; Urano, M.; Ogawa, M.; Yoshida, S.; Mukoyama, H.; Kawai, K.","year":"1963","unstructured":"Sunahara S, Urano M, Ogawa M, Yoshida S, Mukoyama H, Kawai K. Genetic aspect of isoniazid metabolism. Jpn J Hum Genet 1963;8:93-111.","journal-title":"Jpn J Hum Genet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2125.1977.tb00659.x","article-title":"Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens","volume":"4","author":"Ellard, G.A.; Gammon, P.T.","year":"1977","unstructured":"Ellard GA, Gammon PT. Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens. Br J Clin Pharmacol 1977;4:5-14.","journal-title":"Br J Clin Pharmacol"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/0002-9343(63)90104-9","volume":"34","author":"Evans, D.A.P.","year":"1963","unstructured":"Evans DAP. Pharmacogenetics. Am J Med 1963;34: 639-63.","journal-title":"Pharmacogenetics. Am J Med"},{"key":"ref_87","first-page":"367","article-title":"Acetylator phenotype in patients with hydralazine-induced lupoid syndrome","author":"Strandberg, I.; Boman, G.; Hassler, L.; Sjoqvist, F.","year":"1976","unstructured":"Strandberg I, Boman G, Hassler L, Sjoqvist F. Acetylator phenotype in patients with hydralazine-induced lupoid syndrome. Acta Med Scand 1976;200:367-71.","journal-title":"Acta Med Scand"},{"key":"ref_88","first-page":"107","article-title":"Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility","volume":"1","author":"Batchelor, JR, Welsh; KI, Mansilla-Tinoco; R.","year":"1980","unstructured":"Batchelor JR, Welsh KI, Mansilla-Tinoco R, et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1980;i:1 107-9.","journal-title":"Lancet"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0022-5347(24)07113-1","article-title":"The acetylator phenotype of patients with systemic lupus erythematosus","volume":"2","author":"Reidenberg, M.M.; Martin, J.H.","year":"1974","unstructured":"Reidenberg MM, Martin JH. The acetylator phenotype of patients with systemic lupus erythematosus. Drug Metab Dispos 1974;2:71-3.","journal-title":"Drug Metab Dispos"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.0954-6820.1977.tb15686.x","article-title":"Spontaneous systemic lupus erythematosus and acetylator phenotype","author":"Larsson, R.; Karlsson, E.; Molin, L.","year":"1977","unstructured":"Larsson R, Karlsson E, Molin L. Spontaneous systemic lupus erythematosus and acetylator phenotype. Acta Med Scand 1977;201:223-6.","journal-title":"Acta Med Scand"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/art.1780220118","article-title":"Slow acetylation phenotype in systemic lupus erythematosus","volume":"22","author":"Fishbein, E.; Alarcon-Segovia, D.","year":"1979","unstructured":"Fishbein E, Alarcon-Segovia D. Slow acetylation phenotype in systemic lupus erythematosus. Arthritis Rheum 1979;22:95-6.","journal-title":"Arthritis Rheum"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/art.1780200309","article-title":"Acetylator phenotype in systemic lupus erythematosus","volume":"20","author":"Foad, B.; Litwin, A.; Zimmer, H.; Hess, E.V.","year":"1977","unstructured":"Foad B, Litwin A, Zimmer H, Hess EV. Acetylator phenotype in systemic lupus erythematosus. Arthritis Rheum 1977;20:815-8.","journal-title":"Arthritis Rheum"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.1780210203","article-title":"Normal distribution of acetylator phenotypes in systemic lupus erythematosus","volume":"21","author":"Vansant, J.; Woosley, R.L.; John, J.T.; Sergent, J.S.","year":"1978","unstructured":"Vansant J, Woosley RL, John JT, Sergent JS. Normal distribution of acetylator phenotypes in systemic lupus erythematosus. Arthritis Rheum 1978;21:192-5.","journal-title":"Arthritis Rheum"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/art.1780220714","article-title":"Drug acetylation phenotype unrelated to development of spontaneous systemic lupus erythematosus","volume":"22","author":"Morris, R.J.; Freed, C.R.; Kohler, P.F.","year":"1979","unstructured":"Morris RJ, Freed CR, Kohler PF. Drug acetylation phenotype unrelated to development of spontaneous systemic lupus erythematosus. Arthritis Rheum 1979;22: 777-80.","journal-title":"Arthritis Rheum"},{"key":"ref_95","first-page":"126","article-title":"Cutaneous reactions to drugs, acetylation phenotype and HLA antigens in patients with and without systemic lupus erythematosus (SLE)","volume":"8","author":"Johansson, E.A.; Mustakallio, K.K.; Mattila, M.M.; Tiilkainen, A.","year":"1976","unstructured":"Johansson EA, Mustakallio KK, Mattila MM, Tiilkainen A. Cutaneous reactions to drugs, acetylation phenotype and HLA antigens in patients with and without systemic lupus erythematosus (SLE). Ann Clin Res 1976;8:126-8.","journal-title":"Ann Clin Res"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2125.1982.tb01387.x","article-title":"Isoniazid disposition, comparison of isoniazid phenotyping methods in, and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects","volume":"13","author":"Horai, Y.; Ishizaki, T.; Sasaki, T.; Koya, G.; Matsuyama, K.; Iguchi, S.","year":"1982","unstructured":"Horai Y, Ishizaki T, Sasaki T, Koya G, Matsuyama K, Iguchi S. Isoniazid disposition, comparison of isoniazid phenotyping methods in, and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects. Br J Clin Pharmacol 1982; 13:361-74.","journal-title":"Br J Clin Pharmacol"},{"key":"ref_97","first-page":"940","article-title":"Genetic variation in N-acetylation of carcinogenic arylamines by human and rabbit liver","volume":"14","author":"Glowinski, I.B.; Radtke, H.E.; Weber, W.W.","year":"1978","unstructured":"Glowinski IB, Radtke HE, Weber WW. Genetic variation in N-acetylation of carcinogenic arylamines by human and rabbit liver. MolPharmacol 1978;14:940-9.","journal-title":"MolPharmacol"},{"issue":"47","key":"ref_98","first-page":"308","article-title":"Acetylation pattern of different sulphonamides in rapid and slow isoniazid inactivators","volume":"1969","author":"Mattila, M.J.; Tiitinen, H.; Alhava, E.","unstructured":"Mattila MJ, Tiitinen H, Alhava E. Acetylation pattern of different sulphonamides in rapid and slow isoniazid inactivators. Ann Med Exp Biol Fenn 1969;47:308-15.","journal-title":"Ann Med Exp Biol Fenn"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmg.21.4.243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T19:53:09Z","timestamp":1760730789000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmg.21.4.243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984,8]]},"references-count":98,"journal-issue":{"issue":"4","published-online":{"date-parts":[[1984,8,1]]},"published-print":{"date-parts":[[1984,8]]}},"alternative-id":["10.1136\/jmg.21.4.243"],"URL":"https:\/\/doi.org\/10.1136\/jmg.21.4.243","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[1984,8]]}}}